LT2651902T - Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai - Google Patents

Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai

Info

Publication number
LT2651902T
LT2651902T LTEP11807826.0T LT11807826T LT2651902T LT 2651902 T LT2651902 T LT 2651902T LT 11807826 T LT11807826 T LT 11807826T LT 2651902 T LT2651902 T LT 2651902T
Authority
LT
Lithuania
Prior art keywords
pyrazolyl
antioxidant inflammation
inflammation modulators
pyrimidinyl
enones
Prior art date
Application number
LTEP11807826.0T
Other languages
English (en)
Inventor
Eric Anderson
Gary L. Bolton
Bradley Caprathe
Xin Jiang
Chitase Lee
William H. Roark
Melean Visnick
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of LT2651902T publication Critical patent/LT2651902T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP11807826.0T 2010-12-17 2011-12-19 Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai LT2651902T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424601P 2010-12-17 2010-12-17
PCT/US2011/065897 WO2012083306A2 (en) 2010-12-17 2011-12-19 Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Publications (1)

Publication Number Publication Date
LT2651902T true LT2651902T (lt) 2018-01-10

Family

ID=45470714

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11807826.0T LT2651902T (lt) 2010-12-17 2011-12-19 Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai

Country Status (32)

Country Link
US (6) US8513436B2 (lt)
EP (1) EP2651902B1 (lt)
JP (1) JP5857068B2 (lt)
KR (1) KR102000301B1 (lt)
CN (1) CN103596929B (lt)
AR (1) AR084353A1 (lt)
AU (1) AU2011343466B2 (lt)
BR (1) BR112013015241B1 (lt)
CA (1) CA2822071C (lt)
CL (1) CL2013001754A1 (lt)
CO (1) CO6910185A2 (lt)
CY (1) CY1120032T1 (lt)
DK (1) DK2651902T3 (lt)
EA (1) EA025568B1 (lt)
ES (1) ES2653717T3 (lt)
HK (1) HK1189595A1 (lt)
HR (1) HRP20171859T1 (lt)
HU (1) HUE038046T2 (lt)
IL (1) IL226923A (lt)
LT (1) LT2651902T (lt)
ME (1) ME02973B (lt)
MX (1) MX2013006902A (lt)
NO (1) NO2651902T3 (lt)
NZ (1) NZ612788A (lt)
PL (1) PL2651902T3 (lt)
PT (1) PT2651902T (lt)
RS (1) RS56795B1 (lt)
SG (1) SG191181A1 (lt)
SI (1) SI2651902T1 (lt)
TW (1) TWI527788B (lt)
WO (1) WO2012083306A2 (lt)
ZA (1) ZA201305060B (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434151A (zh) 2008-01-11 2018-08-24 里亚塔医药公司 合成三萜类化合物及用以治病之方法
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
LT2651918T (lt) 2010-12-17 2017-10-10 Novartis Ag 5-chlor-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamino kristalinės formos
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
ES2861393T3 (es) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US9464082B2 (en) * 2014-01-24 2016-10-11 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
KR102686868B1 (ko) * 2015-02-12 2024-07-19 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
US11286226B2 (en) 2017-09-21 2022-03-29 Northwestern University Polycyclic carbogenic molecules and uses thereof as anti-cancer agents
US11465963B2 (en) 2017-11-21 2022-10-11 Biogen Ma Inc. Tetrahydronaphthalene derivatives useful as Nrf2 activators
KR20210032936A (ko) * 2018-06-15 2021-03-25 리아타 파마슈티컬즈, 아이엔씨. Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물
WO2019246461A1 (en) * 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
WO2023092034A1 (en) * 2021-11-17 2023-05-25 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875201A (en) 1957-08-28 1959-02-24 Searle & Co Dehydrotigogenone intermediates
US3071577A (en) * 1959-08-13 1963-01-01 Syntex Corp Pyrimidinyl androstanes
US3994935A (en) * 1975-11-24 1976-11-30 E. R. Squibb & Sons, Inc. Steroidal 16β-alkyl[16α,17-b]naphthalenes
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
CN1013672B (zh) * 1983-10-03 1991-08-28 美国辉瑞有限公司 2-氨基-5-羟基-4-甲基嘧啶衍生物的制备方法
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
AU2267995A (en) 1994-04-29 1995-11-29 Takeda Chemical Industries Ltd. Ergoline derivatives as analgesics
JPH08208479A (ja) * 1994-04-29 1996-08-13 Takeda Chem Ind Ltd クラビンアルカロイド誘導体を含有する鎮痛剤
KR100418202B1 (ko) * 1994-09-09 2004-07-05 쇼죠 고야마 분자발현기능의억제방법
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
DE60043400D1 (de) 1999-05-14 2010-01-07 Nereus Pharmaceuticals Inc Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
CA2400626C (en) 2000-02-14 2010-06-01 Merck & Co., Inc. Estrogen receptor modulators
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
WO2002026762A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
EP1395255A4 (en) 2000-11-28 2007-09-12 Univ Texas CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2432148C (en) * 2000-12-28 2011-01-18 Ono Pharmaceutical Co., Ltd. Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
CN1636058B (zh) 2001-05-14 2011-06-08 龚大为 新型丙氨酸转氨酶及其应用方法
EP1418900A4 (en) 2001-08-13 2006-01-25 Merck & Co Inc SELECTIVE ESTROGEN RECEPTOR MODULATORS
EP1444207A2 (en) 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2003062260A1 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
CA2478981A1 (en) 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
EP1660109A4 (en) 2003-09-02 2009-04-08 Unigen Pharmaceuticals Inc FORMULATION OF A MIXTURE OF FREE B-RING FLAVONOIDS AND FLAVANES FOR USE IN THE PREVENTION AND TREATMENT OF COGNITIVE WEAKNESSING AND AGING MEMORY DISORDERS
AU2005282437B2 (en) 2004-09-07 2013-01-10 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
WO2006089406A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
US7902196B2 (en) 2005-03-17 2011-03-08 President And Fellows Of Harvard College Synthesis of avrainvillamide, strephacidin B, and analogues thereof
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
WO2007112043A2 (en) 2006-03-23 2007-10-04 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
JP5610766B2 (ja) 2006-06-27 2014-10-22 ウェリントン ラボラトリーズ インコーポレイティッド グリチルレチン酸誘導体
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
EP4137819A1 (en) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions and uses for treating multiple sclerosis
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
CN108434151A (zh) 2008-01-11 2018-08-24 里亚塔医药公司 合成三萜类化合物及用以治病之方法
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8278311B2 (en) 2008-04-28 2012-10-02 Abbott Laboratories Substituted pyrimidine derivatives
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College 単環式シアノエノンおよびその使用方法説明
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
EP3254675B1 (en) 2009-02-13 2019-05-15 Reata Pharmaceuticals, Inc. Delayed release, oral dosage compositions that contain amorphous cddo-me
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
KR20140017520A (ko) 2010-12-17 2014-02-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 아조사이클릭 아미드
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
LT2683731T (lt) 2011-03-11 2019-07-10 Reata Pharmaceuticals, Inc. C4-monometiltriterpenoido dariniai ir jų panaudojimo būdai
ES2861393T3 (es) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP6272870B2 (ja) 2012-09-10 2018-01-31 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のc17−ヘテロアリール誘導体ならびにその使用方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US20150080465A1 (en) 2013-08-23 2015-03-19 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
US11814338B2 (en) 2023-11-14
AU2011343466A1 (en) 2013-07-25
RS56795B1 (sr) 2018-04-30
CO6910185A2 (es) 2014-03-31
KR102000301B1 (ko) 2019-07-15
PL2651902T3 (pl) 2018-04-30
ZA201305060B (en) 2016-07-27
US20180265455A1 (en) 2018-09-20
JP2014501250A (ja) 2014-01-20
US9174941B2 (en) 2015-11-03
NO2651902T3 (lt) 2018-04-07
EA201390894A1 (ru) 2013-12-30
US20120196880A1 (en) 2012-08-02
US20160130220A1 (en) 2016-05-12
EP2651902A2 (en) 2013-10-23
BR112013015241B1 (pt) 2022-03-29
US11192852B2 (en) 2021-12-07
WO2012083306A2 (en) 2012-06-21
CA2822071A1 (en) 2012-06-21
PT2651902T (pt) 2018-02-01
HRP20171859T1 (hr) 2018-01-26
US20220281807A1 (en) 2022-09-08
CY1120032T1 (el) 2018-12-12
US8513436B2 (en) 2013-08-20
IL226923A (en) 2016-06-30
US9884809B2 (en) 2018-02-06
CA2822071C (en) 2019-07-16
ES2653717T3 (es) 2018-02-08
EA025568B1 (ru) 2017-01-30
HK1189595A1 (zh) 2014-06-13
CN103596929A (zh) 2014-02-19
US20200207706A1 (en) 2020-07-02
US20140051739A1 (en) 2014-02-20
JP5857068B2 (ja) 2016-02-10
DK2651902T3 (en) 2018-01-08
HUE038046T2 (hu) 2018-09-28
MX2013006902A (es) 2013-10-17
NZ612788A (en) 2015-10-30
SI2651902T1 (en) 2018-02-28
ME02973B (me) 2018-07-20
SG191181A1 (en) 2013-07-31
CN103596929B (zh) 2016-10-19
BR112013015241A2 (pt) 2021-04-20
CL2013001754A1 (es) 2013-11-29
WO2012083306A3 (en) 2012-10-11
AU2011343466B2 (en) 2017-01-05
AR084353A1 (es) 2013-05-08
TWI527788B (zh) 2016-04-01
EP2651902B1 (en) 2017-11-08
TW201249785A (en) 2012-12-16
KR20130130784A (ko) 2013-12-02

Similar Documents

Publication Publication Date Title
HK1189595A1 (zh) 作為抗氧化發炎調節劑的吡唑及嘧啶三環烯酮
EP2844247A4 (en) ROR MODULATORS AND ITS USES
EP2926333A4 (en) Microcup compositions
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
EP2742112A4 (en) CARBAZOLOCARBAZOL-BIS (DICARBOXIMIDES) AND THEIR USE AS SEMICONDUCTORS
EP3680160B8 (de) Selbstverriegelnde kompakt-kupplung
EP2582836A4 (en) PRPK-TPRKB MODULATORS AND ITS APPLICATIONS
EP2830654B8 (en) Methods and compositions for treating inflammation
EP2828822A4 (en) SYSTEMS AND METHODS FOR ISO-CREATIVE POWER REDUCTION FOR INDICATORS
EP2524318A4 (en) Syndication of multiple service instances
EP2892913A4 (en) Peptides and their uses
SG184372A1 (en) Polycyclic tetracycline compounds
EP2844260A4 (en) ROR MODULATORS AND ITS USES
GB201214736D0 (en) Inflammation imaging and therapy
PL2346018T3 (pl) Szyld przenośny
AU2010100529A4 (en) Aisle sign
AU2012905152A0 (en) Transportable Structure
AU2012902073A0 (en) Lenseless and mirrorless telescope
AU2012101565A4 (en) Display Means
EP2638160B8 (en) Nuclions and ribocapsids
AU2012905095A0 (en) Compositions and uses thereof
AU2012904257A0 (en) Shoo!
AU2012904202A0 (en) Shoo!
AU2012902771A0 (en) Display
AU2011902984A0 (en) Compositions and their use